Literature DB >> 8529406

Immunohistochemical studies on melanin associated antigen (MAA) induced experimental autoimmune anterior uveitis (EAAU).

M C Kim1, N H Kabeer, M T Tandhasetti, H J Kaplan, N S Bora.   

Abstract

Experimental autoimmune anterior uveitis (EAAU), a model of uveitis induced by sensitization to melanin associated antigen (MAA) derived from the iris and ciliary body, closely resembles human acute anterior uveitis. The immunopathogenesis of EAAU was studied by immunohistochemical detection of immune cells and the expression of Ia, ICAM-1 and LFA-1 antigens. Male Lewis rats were immunized with bovine MAA, mixed with CFA and pertussis toxin in the hind foot pad. Animals were examined daily by slit-lamp biomicroscopy and serially sacrificed up to 30 days. Immunohistology of the enucleated eyes was performed with monoclonal antibodies W3/25 (CD4), OX-8 (CD8), ED2 (macrophage), OX-33 (B cell), OX-6 (Ia), IA29 (ICAM-1) and WT.1 (LFA-1). During each stage of EAAU, CD4+ T cells predominated over both CD8+ T cells and macrophages in the uvea. Very few B cells were detected during each stage of EAAU. EAAU could not be induced by the adoptive transfer of sera obtained from immunized animals. Low levels of constitutive ICAM-1 and Ia were observed. An increase in ICAM-1 expression was first noted on the epithelial cells of the uveal tract and RPE on day 9 post immunization and preceded LFA-1 and Ia upregulation by approximately 2 days. The immunopathogenesis of EAAU appears to be linked to the presence of the CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8529406     DOI: 10.3109/02713689508998498

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  18 in total

1.  Apoptosis of CD4+ T cells occurs in experimental autoimmune anterior uveitis (EAAU).

Authors:  H G Yu; H Chung; W J Lee
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  Tolerance to melanin-associated antigen in autoimmune uveitis is mediated by CD4+CD25+ T-regulatory cells.

Authors:  Bharati Matta; Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Am J Pathol       Date:  2008-10-02       Impact factor: 4.307

Review 3.  Immunopathology of uveitis.

Authors:  C C Chan; Q Li
Journal:  Br J Ophthalmol       Date:  1998-01       Impact factor: 4.638

4.  Experimental melanin-induced uveitis in the Fischer 344 rat is inhibited by anti-CD4 monoclonal antibody, but not by mannose-6-phosphate.

Authors:  J R Smith; P H Hart; C R Parish; S D Standfield; D J Coster; K A Williams
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

Review 5.  Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype?

Authors:  Kenneth G-J Ooi; Grazyna Galatowicz; Virginia L Calder; Susan L Lightman
Journal:  Clin Med Res       Date:  2006-12

6.  Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis.

Authors:  J Ambati; K B Wynne; M C Angerame; M R Robinson
Journal:  Br J Ophthalmol       Date:  1999-10       Impact factor: 4.638

Review 7.  The role of complement system in ocular diseases including uveitis and macular degeneration.

Authors:  Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

Review 8.  Biologic agents in experimental autoimmune uveitis.

Authors:  Gian Paolo Giuliari; Ama Sadaka; David M Hinkle
Journal:  Int Ophthalmol       Date:  2013-03-14       Impact factor: 2.031

9.  Human RPE cell apoptosis induced by activated monocytes is mediated by caspase-3 activation.

Authors:  Susan G Elner; Ayako Yoshida; Zong-Mei Bian; Andrei L Kindezelskii; Howard R Petty; Victor M Elner
Journal:  Trans Am Ophthalmol Soc       Date:  2003

10.  Antigen-specific tolerance inhibits autoimmune uveitis in pre-sensitized animals by deletion and CD4+CD25+ T-regulatory cells.

Authors:  Bharati Matta; Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Immunol Cell Biol       Date:  2009-11-03       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.